ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to
evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of
ALT-801 and its effects on glucose control in overweight and obese subjects with type 2
diabetes mellitus (T2DM).